Updated CRO Services for Cell and Gene Therapy Launched at Creative Biolabs

Creative Biolabs, a leading contract research organization (CRO) focused on cell and gene therapy, is proud to announce the launch of updated services including CAR-Macrophage therapy development service and viral vector construction service.

New York City, New York Feb 27, 2023 (Issuewire.com) - Cell and Gene therapy presents some of the most exciting opportunities for emerging drugs, becoming increasingly popular treatments for various diseases in recent years. With so much research focusing on this direction, Creative Biolabs has been dedicated to upgrading the technology platforms and the service portfolio for cell and gene therapy development, aiming at helping clients get access to advanced technologies, expertise from experienced professionals, and reliable results ready to be applied for the downstream research.

One of the main updates recently is about the <u>chimeric antigen receptor macrophage (CAR-MA) therapy</u> development service. Creative Biolabs has updated the CellRapeuticsTM Chimeric Antigen Receptor (CAR) Technology, and based on this, the team extends the line-up of service offerings to cover target identification & selection, high-affinity antigen binder generation, CAR design & construction, CAR-MA preparation service, macrophages activation, and expansion service, in vitro assessments, and preclinical tests and clinical trials.

By leveraging their expertise in cell therapy development and manufacturing, scientists at Creative Biolabs are well-positioned to support clients in the development of this exciting new therapeutic modality, especially for solid tumor treatment.

Another update is the viral vector design and construction service, which is a key component of gene therapy, as these vectors are used to deliver therapeutic genes to target cells. The viral vector service at Creative Biolabs offers a range of <u>viral vector construction</u> systems, including integrating and non-integrating viral vectors, covering lentiviral vectors, adenovirus vectors, herpes simplex virus vectors, vaccinia viral vectors, adeno-associated virus vectors, baculovirus vectors, alphavirus vectors, flavivirus vectors, measles virus vectors, foamy virus vectors, helper-dependent adenoviral vectors, and capsid-modified <u>oncolytic virus</u> vectors.

The sophisticated scientist team provides comprehensive consultation services about the selection of viral vectors for gene therapy, and ensures high efficiency and safety.

"We are excited to announce the renovation of our CAR-macrophage therapy development service and viral vector construction service," said a senior scientist at Creative Biolabs. "These reflect our commitment to advancing the field of cell and gene therapy and our dedication to providing our clients with the most comprehensive and innovative solutions for their development programs.

About Creative Biolabs

Creative Biolabs is the leading custom service provider with extensive experience in antibody therapeutics discovery and cell & gene therapy development. The service and product portfolio offered by the all-star team is reputable among worldwide regular customers for flexibility and efficiency. To improve the lab's efficiency, get accurate data, and decrease the time to market, personalized solutions can be tailored to streamline the whole workflow or adapted to any step of a project.

Media Contact

Creative Biolabs

marketing@creative-biolabs.com

Source: Creative Biolabs

See on IssueWire